Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years.
Rawoot
A
A
Little
F
F
Heckmann
J M
JM
D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy*; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D012307:Risk Factors; D013019:South Africa / Q000453:epidemiology
D007166:Immunosuppressive Agents; D001379:Azathioprine